Starling Oncology, Inc. (STLN)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch STLN
See up to 3 months of STLN. The 7-day demo opens the 1M and 3M ranges and puts STLN on your watchlist.
Start 7-day demoLatest STLN insider trades
- Brad Hively - DirectorOpen-market sale$1.95M
Jorey Chernett - 10% OwnerOpen-market purchase$78K
About Starling Oncology, Inc. (STLN)
Starling Oncology, Inc. is an SEC registrant, filing under CIK 0001799191, classified as offices and clinics of doctors of medicine. We track it alongside the rest of the Health Care sector.
STLN Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 30,000 | $173K |
| Open-market sale | 4 | 322,405 | $2.10M |
| Grant or award | 7 | 222,890 | |
STLN insider transactions (Form 4)
3879 Form 4 filings on record, the earliest from Nov 18, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Brad Hively - Director | Open-market sale | Common Stock | 298,853 | $6.51 footnote F1 | $1.95M | |
| ||||||
| Jorey Chernett - 10% Owner | Open-market purchase | Common Stock | 12,000 | $6.54 | $78K | |
| Jorey Chernett - 10% Owner | Open-market sale | Call Option (STLN 19FEB27 $9C) | 100 | $6.24 | $624 | |
| Mohit Kaushal - Director | Grant or award | Common Stock | 33,133 | $0.00 | - | |
| Anne McGeorge - Director | Grant or award | Common Stock | 41,165 | $0.00 | - | |
| Mark L. Pacala - Director | Grant or award | Common Stock | 30,120 | $0.00 | - | |
 Mark Stolper - Director | Grant or award | Common Stock | 31,124 | $0.00 | - | |
| Kimberly Jo Tzoumakas - Director | Grant or award | Common Stock | 29,116 | $0.00 | - | |
| Brad Hively - Director | Grant or award | Common Stock | 27,108 | $0.00 | - | |
| Karen Marie Johnson - Director | Grant or award | Common Stock | 31,124 | $0.00 | - | |
| Jorey Chernett - 10% Owner | Open-market purchase | Common Stock | 18,000 | $5.27 footnote F1 | $95K | |
| ||||||
| Yale Podnos - Officer | Option exercise | Common Stock | 17,974 | $1.87 | $34K | |
| Yale Podnos - Officer | Option exercise | Common Stock | 5,478 | $2.00 | $11K | |
| Yale Podnos - Officer | Open-market sale | Common Stock | 17,974 | $6.43 | $116K | |
| Yale Podnos - Officer | Open-market sale | Common Stock | 5,478 | $6.35 | $35K | |
| Yale Podnos - Officer | Option exercise | Stock Option (Right to Buy) | 17,974 | $1.87 | $34K | |
| Yale Podnos - Officer | Option exercise | Stock Option (Right to Buy) | 5,478 | $2.00 | $11K | |
| Jorey Chernett - 10% Owner | Open-market purchase | Common Stock | 15,000 | $5.85 footnote F1 | $88K | |
| ||||||
| Kimberly Jo Tzoumakas - Director | Grant or award | Common Stock | 17,185 | $0.00 | - | |
| Mark Stolper - Director | Grant or award | Common Stock | 25,833 | $0.00 | - | |
| Jorey Chernett - 10% Owner | Open-market purchase | Common Stock | 18,000 | $5.02 footnote F1 | $90K | |
| ||||||
| Yale Podnos - Officer | Open-market sale | Common Stock | 23,451 | $5.38 | $126K | |
| Jorey Chernett - 10% Owner | Open-market purchase | Common Stock | 12,000 | $4.75 | $57K | |
| Yale Podnos - Officer | Other | Common Stock | 1,805 | $4.47 | $8K | |
| Daniel Virnich - Officer | Other | Common Stock | 23,058 | $4.47 | $103K | |
| Robert Ross Carter - Officer | Other | Common Stock | 1,604 | $4.47 | $7K | |
| Jorey Chernett - 10% Owner | Open-market purchase | Common Stock | 5,000 | $4.05 | $20K | |
| Jorey Chernett - 10% Owner | Open-market purchase | Common Stock | 33,500 | $4.07 footnote F1 | $136K | |
| ||||||
| Jorey Chernett - 10% Owner | Open-market purchase | Common Stock | 30,000 | $4.09 | $123K | |
| Mohit Kaushal - Director | Open-market sale | Common Stock | 57,286 | $3.50 footnote F2 | $201K | |
| Mohit Kaushal - Director | Open-market sale | Common Stock | 38,433 | $3.50 footnote F3 | $135K | |
| ||||||
| Jorey Chernett - 10% Owner | Open-market purchase | Common Stock | 20,000 | $3.10 | $62K | |
 Jeffrey Langsam - Officer | Grant or award | Common Stock | 70,270 footnote F1 | $0.00 | - | |
| ||||||
| Kristin England - Officer | Grant or award | Common Stock | 55,743 footnote F1 | $0.00 | - | |
| ||||||
| Yale Podnos - Officer | Grant or award | Common Stock | 66,446 footnote F1 | $0.00 | - | |
| Yale Podnos - Officer | Other | Common Stock | 16,173 footnote F2 | $3.07 | $50K | |
| ||||||
| Robert Ross Carter - Officer | Grant or award | Common Stock | 202,914 footnote F1 | $0.00 | - | |
| Robert Ross Carter - Officer | Other | Common Stock | 20,320 footnote F2 | $3.07 | $62K | |
| ||||||
Item 5.02
Item 1.01, 2.03, 9.01
Item 2.02, 9.01
Item 5.03, 7.01, 9.01
Recent STLN Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| BRADFORD HIVELY | Director | 298,853 | $1.95M | View on EDGAR | |
| - | - | - | - |
STLN insider trading FAQ
What is the latest insider trade for STLN?
Starling Oncology, Inc. (STLN) had 11 insider filings in the last 90 days, with the most recent on 2026-08-24. The full record for STLN runs to 79 Form 4 filings, the earliest from 2024-11-18. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying STLN stock?
2 insider purchases of STLN were filed in the last 90 days, totaling $173K.
How many insiders are selling STLN stock?
4 insider sales of STLN were filed in the last 90 days, totaling $2.10M.
Where can I see STLN SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects STLN Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Brad Hively view on EDGAR
- - Jorey Chernett view on EDGAR
- - Mohit Kaushal view on EDGAR
- - Anne McGeorge view on EDGAR
- - Mark L. Pacala view on EDGAR
- - Mark Stolper view on EDGAR
- - Kimberly Jo Tzoumakas view on EDGAR
- - Brad Hively view on EDGAR
- - Karen Marie Johnson view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where STLN's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow STLN with a 7-day demo
- STLN on your watchlist
- Every STLN Form 4 filing on record
- Up to 3 months of STLN price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
